Payment overview · 2025
General Payments
$436.03
25 reported records · 8 companies
Healthcare provider profile · identity verified
Garry Lee Brady, DO
Allopathic & Osteopathic Physicians|General Practice · RENSSELAER, IN · NPI 1457513764
Verified facts
What the public records show
CMS Open Payments records show Garry Lee Brady, DO received $436.03 in general payments during 2025 across 25 reported records.
ABBVIE INC. accounted for 54.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nuedexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $236.17 | 54.2% | 14 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $58.08 | 13.3% | 3 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $42.57 | 9.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $30.48 | 7.0% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $19.60 | 4.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.81 | 4.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.77 | 4.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.55 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $436.03 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $129.54 | 7 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $59.12 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $58.08 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $47.51 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $47.51 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $43.87 | 3 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $42.57 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $30.48 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.77 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 301 | 36 |
| Levothyroxine Sodium | Levothyroxine Sodium | 294 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 201 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 151 | 17 |
| Amlodipine Besylate | Amlodipine Besylate | 142 | 32 |
| Potassium Chloride | Potassium Chloride | 139 | 28 |
| Eliquis | Apixaban | 138 | 13 |
| Furosemide | Furosemide | 132 | 36 |
| Metformin Hcl | Metformin Hcl | 131 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 127 | 49 |
| Levetiracetam | Levetiracetam | 122 | suppressed |
| Alprazolam | Alprazolam | 121 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 121 | 15 |
| Losartan Potassium | Losartan Potassium | 120 | 26 |
| Sertraline Hcl | Sertraline Hcl | 119 | 21 |
| Allopurinol | Allopurinol | 113 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 101 | 35 |
| Memantine Hcl | Memantine Hcl | 92 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 18 |
| Donepezil Hcl | Donepezil Hcl | 85 | 13 |
| Baclofen | Baclofen | 78 | suppressed |
| Lisinopril | Lisinopril | 76 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 11 |
| Prednisone | Prednisone | 71 | 30 |
| Azithromycin | Azithromycin | 67 | 37 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 66 | suppressed |
| Digoxin | Digoxin | 62 | suppressed |
| Gabapentin | Gabapentin | 62 | 21 |
| Raloxifene Hcl | Raloxifene Hcl | 61 | suppressed |
| Omeprazole | Omeprazole | 58 | 25 |
| Tramadol Hcl | Tramadol Hcl | 57 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 55 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | suppressed |
| Nifedipine Er | Nifedipine | 54 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 53 | 13 |
| Bumetanide | Bumetanide | 52 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 51 | 21 |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 51 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 50 | 11 |
| Simvastatin | Simvastatin | 49 | 16 |
| Trazodone Hcl | Trazodone Hcl | 48 | 16 |
| Amoxicillin | Amoxicillin | 46 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | suppressed |
| Topiramate | Topiramate | 43 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 41 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 40 | suppressed |
| Cilostazol | Cilostazol | 39 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | 14 |
| Ozempic | Semaglutide | 38 | suppressed |
| Fluconazole | Fluconazole | 37 | 18 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 36 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 35 | 12 |
| Prazosin Hcl | Prazosin Hcl | 32 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 31 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 30 | 11 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 29 | suppressed |
| Metolazone | Metolazone | 29 | suppressed |
| Latanoprost | Latanoprost | 28 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Carvedilol | Carvedilol | 24 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | 12 |
| Famotidine | Famotidine | 23 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | 13 |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 11 |
| Clonazepam | Clonazepam | 18 | suppressed |
| Ivermectin | Ivermectin | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Nystatin | Nystatin | 12 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $436.03 · 25 records | ABBVIE INC. | ACTHAR, AIRSUPRA, CAPLYTA, CREON, Kerendia, LINZESS, OTEZLA, QULIPTA, REPATHA, REXULTI, SUBLOCADE, UBRELVY, VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error